CRISPR Therapeutics (NASDAQ:CRSP) is one of the best stocks for 20 years. On February 12, CRISPR Therapeutics announced its ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.
Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...
CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...
CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient ...
We expect CRISPR Therapeutics CRSP to surpass expectations when it reports fourth-quarter and full-year 2025 results. The company’s earnings beat estimates by 11.36% in the last reported quarter. The ...
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the March 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results